Acorn Capital Advisors, LLC holds a concentrated book of 20 reported positions worth $366.5M as of Q2 2026 (disclosed Aug 14, 2026, a ~45-day 13F lag). This quarter Engene Therapeutics Inc first appears in 13F filings, a listing rather than a purchase; they trimmed Bicara Therapeutics Inc. Their largest long position is CG Oncology Inc at 22% of the reported non-option book. Cloning the disclosed picks since 2025 would be +90% (+50.5%/yr). That is a simulation of the disclosed long book, not audited returns.
Following at the filing date actually beat the quarter-end book by 8.5 points over this window.
Growth of $10,000 cloning Acorn Capital Advisors, LLC's disclosed long 13F book, rebalanced on each filing date (so it reflects each quarter's actual reporting lag, ~45 days for the latest filing, with no look-ahead), total-return basis (dividends reinvested), derived from end-of-day prices. “Their reported book” values the same picks from quarter-end, before they were public. S&P 500 is SPY total return over the same window. Excludes shorts, cash, options and non-13F holdings. Not investment advice.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
100% mapped to company sectors
+1 sector below the cut, under 0.5% together
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices (an exit at the prior quarter-end), no cost basis
Other tracked managers holding the same core names as Acorn Capital Advisors, LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| Foresite Capital Management VI LLC | 4 / 20 | $209.5M |
| Avidity Partners Management LP | 4 / 20 | $146.3M |
| NEA Management Company, LLC | 4 / 20 | $258.7M |
| KVP Capital Advisors, LP | 3 / 20 | $18.0M |
| Superstring Capital Management LP | 5 / 20 | $18.7M |
| Jones Hill Capital LP | 2 / 20 | $51.5M |
| Vivo Capital, LLC | 3 / 20 | $112.1M |
| Stonepine Capital Management, LLC | 3 / 20 | $14.2M |
Ranked by the share of each fund's own book sitting in the names it shares with Acorn Capital Advisors, LLC: only funds sharing at least a tenth of the book qualify. Index giants, bank custody books and market makers are excluded. They hold everything, so their overlap says nothing.
Bars show each position's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | CG Oncology Inc COM | $80.4M | 1.13M | 21.9% | ▲+0.1% Added · +999 sh | |
| 2 | Urogen Pharma Ltd COM | $61.6M | 1.67M | 16.8% | —Held | |
| 3 | Trevi Therapeutics Inc COM | $40.0M | 2.14M | 10.9% | —Held | |
| 4 | Candel Therapeutics Inc COM | $36.0M | 3.50M | 9.8% | —Held | |
| 5 | Puma Biotechnology Inc COM | $33.5M | 4.13M | 9.1% | —Held | |
| 6 | Jade Biosceinces Inc COM NEW | $21.9M | 986.8K | 6.0% | ▲+25% Added · +200K sh | |
| 7 | Bicara Therapeutics COM | $19.1M | 643.4K | 5.2% | ▼~0% Reduced · −1 sh | |
| 8 | Karyopharm Therapeutics Inc COMMON STOCK | $14.8M | 1.52M | 4.0% | ▲+427% Added · +1.2M sh | |
| 9 | Onkure Therapeutics Inc CLASS A COM | $12.9M | 2.84M | 3.5% | —Held | |
| 10 | Helus Pharma Inc. COM STK | $10.2M | 1.54M | 2.8% | —Held | |
| 11 | Protara Therapeutics Inc COM STK | $6.7M | 1.75M | 1.8% | —Held | |
| 12 | Aura Biosciences Inc COM | $6.6M | 929.1K | 1.8% | ▲+56% Added · +333K sh | |
| 13 | Leonabio, Inc. COMMON STOCK | $5.8M | 634.5K | 1.6% | —Held | |
| 14 | Verastem Inc COM | $5.6M | 1.47M | 1.5% | —Held | |
| 15 | Whitehawk Therapeutics Inc COM | $5.2M | 1.14M | 1.4% | —Held | |
| 16 | Q32 Bio Inc. COM | $2.8M | 216.2K | 0.8% | ▼−31% Reduced · −99K sh | |
| 17 | Eugene Therapeutics COM | $2.2M | 1.27M | 0.6% | →Listed Newly reportable | |
| 18 | Jasper Therapeutics COM | $604K | 1.44M | 0.2% | ▲+1.9% Added · +27K sh | |
| 19 | Bioatla Inc COM | $448K | 108.1K | 0.1% | ▼−98% Reduced · −5.3M sh | |
| 20 | Vyne Therapeutics Inc COM | $926 | 1.4K | <0.1% | —Held |
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/2054410/holdings"
Use Arkolith to show ACORN CAPITAL ADVISORS, LLC's latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
Reported 13F total per quarter. Raw filing totals can include option notional.
| Quarter | As of | Filed | Lag | Positions | Value | Form |
|---|---|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | Aug 14, 2026 | 45d | 20 | $366.5M | 13F-HR |
| Q1 2026 | Mar 31, 2026 | May 15, 2026 | 45d | 22 | $351.8M | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 17, 2026 | 48d | 21 | $295.1M | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 17, 2025 | 48d | 20 | $197.0M | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 45d | 21 | $152.9M | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 19, 2025 | 49d | 22 | $149.9M | 13F-HR/A |
| Q4 2024 | Dec 31, 2024 | May 19, 2025 | 139d | 21 | $185.8M | 13F-HR/A |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. Book totals and portfolio weights cover reported non-option positions, which can include notes and warrants. Disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.